From the therapeutic aspect, DPP4 inhibitors have been introduced in the market from 2006 (16) and quite interestingly several randomized control trials (RCT) have reported better glycemic control achieved by these drugs specifically for the Asian population where there is a large population of non-obese T2DM (17, 18). Here, DPP4 is linked to type 2 diabetes mellitus.